Abstract

Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants

Author(s): Riepl Mike

Issue: Jan/Feb 2023 - Volume 27, Number 1

Page(s): 12-21

Download in electronic PDF format for $75
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 1
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 2
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 3
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 4
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 5
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 6
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 7
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 8
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 9
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Page 10

Abstract

COVID-19 (coronavirus disease 2019), which is caused by the positive-stranded ribonucleic acid virus SARS-CoV-2 (acute respiratory syndrome coronavirus 2), is an extremely contagious airborne illness of pandemic proportions. In the modern era, few diseases other than COVID-19 have produced such severe, prolific, and protean short-term adverse effects and long-term sequelae. In addition, few other pandemics have exhibited a trajectory of morbidity and mortality so affected by social, economic, and political factors as well as individual personal perceptions and beliefs. Vaccines for the prevention of SARS-CoV-2 infection and treatments for COVID-19 mitigate associated morbidity and mortality, but an increasing array of variants presents challenges to therapeutic effectiveness. As a result, afflicted patients often require customized treatments that address the severity of their infection, the manifestations of disease they exhibit, and their individual pharmacogenomic profile. In such cases, a compounded preparation may offer needed support for recovery. This article, which is the first in a series on compounding for COVID-19 and long COVID (i.e., the long- term sequelae of SARS-CoV-2 infection), provides information about pertinent viral terminology and a brief overview of SARS-CoV-2 mutations and variants of note. Two formulations for customized compounds that may prove effective in treating the acute and/or long-term effects of COVID-19 when commercial therapies have failed are also provided.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2023
Pg. 12-21
Author(s): Riepl Mike
Jul/Aug 2023
Pg. 284-293
Author(s): Riepl Mike, Kaiser Joe
May/Jun 2023
Pg. 192-200
Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023
Pg. 98-107
Author(s): Riepl Mike
Sep/Oct 2023
Pg. 368-380
Author(s): Riepl Mike, Kaiser Joe
Jul/Aug 2020
Pg. 287-295
Author(s): McElhiney Linda F
Jul/Aug 2020
Pg. 268
Author(s): Allen Loyd V Jr
Sep/Oct 2020
Pg. 358-364
Mar/Apr 2021
Pg. 109-113
Jul/Aug 2003
Pg. 288-291
Author(s): Glasnapp Andrew
Jul/Aug 2020
Pg. 316
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 310
Author(s): Stockton Shelly J
Jul/Aug 2021
Pg. 268
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 266-270
Author(s): Kuntz Rachael
Sep/Oct 2022
Pg. 432-435
Jul/Aug 2016
Pg. 347-350
Jul/Aug 2021
Pg. 296-297
Author(s): Brunner Scott
Sep/Oct 2021
Pg. 386-387
Author(s): Brunner Scott
May/Jun 2003
Pg. 188-191
Author(s): Davidson Gigi S
Mar/Apr 2022
Pg. 100-109
Author(s): Broughel James